IDT CMAX

IDT CMAX

CMAX, IDT OPENS A NEW FACILITY IN ADELAIDE

Established in 1993, CMAX is one of Australia’s largest, longest running and most experienced, dedicated clinical trials unit.

Our team specialises in a range of early-phase clinical trials, including first-time in human-studies – of which we’ve conducted more than 100 to date.

IDT-CMAX

With an impressive global regulatory history and a database of more than 13,000 active volunteers, our brand new 50-bed Phase I (through to Phase II-IV) unit includes a 24-bed ambulatory cardiac telemetry monitoring system and is centrally located to Adelaide’s Biomed City.

 

LOCAL & GLOBAL PARTNERSHIPS

“Our specialist teams strive to ensure the very best outcomes for patients and clients whilst conducting leading research with agile startups as well as the world’s top pharmaceutical companies. We hold ourselves to the highest standards, working with our government and industry partners to benefit the health outcomes of communities world-wide.”
Mr Graeme Kaufman, Chairman, IDT Australia.

IDT-Locala-dn-Global-Partnerships
Our partnerships and trials have resulted in the advancement of global medicines and technologies, from cancer treatments, to early warning bio-devices and hormone replacement therapies.

 

ASSISTED STUDY APPROVALS

By using the CTN scheme we can assist you fast-track your clinical trial, eliminating the time and cost associated with filing an Investigational New Drug (IND) application.

Studies are initiated on approval by a local human research ethics committee (HREC), typically within six weeks of submission. The Therapeutic Goods Administration (TGA), Australia’s regulatory body, is notified of the impending study by way of the Australian Clinical Trial Notification (CTN), but it does not need to give approval before commencement.

 

AUSTRALIAN R&D TAX INCENTIVES

All of our studies are fully ICH GCP compliant and comply with the registration requirements of the US FDA, EMEA, Japanese MHW and Canadian HPB; we have been US FDA-audited.

We can assist our overseas clients register for the Australian R&D Tax Incentive scheme. This allows eligible companies to claim up to a 45% rebate on qualifying R&D spend – for more information contact our experienced team today.

CMAX, IDT Australia Opens a new Clinical Trials Facility in Adelaide

On Friday 29 April IDT Australia Chairman Mr Graeme Kaufman, together with The Hon. Katrine Hildyard MP Assistant Minister to the Premier, Member for Reynell representing the Hon. Jack Snelling MP Minister for Health Industries, launched a new purpose built clinical trials facility in central Adelaide.

Click here for further details.

Areas of Expertise

We have run a large number of trials in a wide range of therapeutic areas:

Pain / Anaesthesia (inc. S8)
Dermatology
Metabolism / Endocrinology
Infectious Diseases
Vaccine
Monoclonal Antibody
Neurological
Oncology
Women’s Health
Allergy / Respiratory
Renal
Gastrointestinal
Cardiovascular
Rheumatology
Japanese
Haematology